<img src="https://ml.globenewswire.com/Resource/Download/23b7005f-0a6e-4435-9c38-b63e6e155cc5?size=2" nborder="0" align="left" hspace="5" vspace="5" title="TN Logo" alt="TN Logo"/>Findings from the largest prospective WEB pooled dataset strengthen the clinical evidence supporting WEB treatment across distinct ruptured and unruptured aneurysm cohorts.Aliso Viejo, CA, Aug. 31, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Aliso Viejo, Calif. – August 31, 2026 – Terumo Neuro, a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced two separate peer-reviewed publications reporting 1-year outcomes from the WISE (WEB Implant Safety and Long-term Efficacy) study. The publications report distinct 1-year subgroup analyses: one evaluating patients with ruptured intracranial aneurysms and one evaluating patients with unruptured intracranial aneurysms, both treated with the WEB Device. The launch of the WEB Aneurysm Embolization System helped create the intrasaccular treatment category, and with more than 15 years of clinical experience, Terumo Neuro continues to advance the field through ongoing investment in intrasaccular evidence generation, data collection, and patient outcomes. WISE is the largest prospective, multicenter study evaluating the long-term safety and effectiveness of WEB in a broad global patient population. The study combines data from seven prospective, multicenter, single-arm, core laboratory-adjudicated, Good Clinical Practice (GCP)-compliant studies conducted across Europe, North America, and Asia, with a total of 601 patients, including 143 patients with ruptured aneurysms and 449 patients with unruptured aneurysms.1, 2 "WISE examines patient-level data from 601 patients, pooling and fully reanalyzing safety and effectiveness outcomes across a broad population. All studies contributing to WISE were independently core lab and safety adjudicated, with all 7 studies utilizing the same core lab and the majority using the same clinical events adjudicator, enhancing the meaningfulness of the outcomes," said Sheila Warner, Sr. Director, Medical Affairs, at Terumo Neuro. Publication of the 1-year ruptured subgroup and unruptured subgroup findings represent an important milestone for WEB clinical evidence. Together, they provide clinical evidence supporting the safety and effectiveness of the WEB device across both ruptured and unruptured aneurysms. Among patients with ruptured wide-neck bifurcation aneurysms, the published 1-year results demonstrated:2 <ul><li>0% rebleeding after WEB treatment through one year.</li><li>0% treatment-related mortality and 1.6% treatment-related morbidity at one year.</li><li>97.2% technical success, including 100% technical success in aneurysms measuring 6 mm or smaller.</li><li>87.5% adequate aneurysm occlusion at one year, increasing to 93.5% in aneurysms measuring 6 mm or smaller.</li><li>6.5% retreatment rate through one year.</li></ul> Among patients with unruptured wide-neck bifurcation aneurysms, the published 1-year results demonstrated:1 <ul><li>0% aneurysm ruptures after WEB treatment through one year.</li><li>&lt;1% treatment-related morbidity and 0% device-related mortality at one year.</li><li>Low aneurysm recurrence (6.4%) and retreatment rate (2.5%) through one year.</li><li>98% technical success and ~20-minute procedure times.</li></ul> "WISE is an important study and could serve as a model for how the industry moves forward. By assembling seven studies into a single patient-level database, we can conduct advanced, granular analyses of WEB data to better understand which patients are best suited for treatment, how the device can be used most safely, and how we can achieve the best possible outcomes," said Dr. David Fiorella, Director of the Cerebrovascular Center at Stony Brook Medicine. The published 1-year results for both ruptured and unruptured aneurysms establish an important clinical foundation for the WEB Device. With more than 600 enrolled patients, WISE creates opportunities for meaningful analyses across  patient and aneurysm characteristics and treatment strategies, further expanding the understanding of WEB across a broad range of aneurysm types, locations, sizes, and geographies. Recently presented 5-year data continue to build upon these findings by providing important insight into the long-term durability of WEB treatment. The WISE Study reflects Terumo Neuro's continued commitment to generating long-term clinical evidence supporting the WEB Aneurysm Embolization System. The WISE <a href="https://www.globenewswire.com/Tracker?data=ilvrHC1lObHD4WlFeHVxlbJ4a9Ebj7wCpKw6ZXWqJvcxsM7AALW4sD_bpjuUpK5QuNQqSz8lnkIKHOFxnW4-N4KpH668C4vl_WhBFSFloUyuoW4g27G7Q848piN0m5tw3FpW9WZ0NcXxHe8O67DgTwIafF5o6WL9-P5LtTcdses=" rel="nofollow" target="_blank" title="ruptured">ruptured</a> and <a href="https://www.globenewswire.com/Tracker?data=Br5yKDyeBVXY1m2xRAXrUsYuoDoQ9IS3zb_-z6qteCvsjefkX84gZ6Nw1dDdGVpAOuLiwwRBFRotTq9Nso6_B0qArYtBl9IOfmIS5dqcVu6NltBq6ddZUmQOsSSjuj2Rzgl2m8ok_MZkH4wSzHoWOYDxc3Rt8OOVnzatsuhWcZo=" rel="nofollow" target="_blank" title="unruptured">unruptured</a> study results are now available in the Journal of NeuroInterventional Surgery.1,2 For more information, contact: Rebecca Janzon, Terumo Neuro Email: <a href="https://www.globenewswire.com/Tracker?data=OLayiWdFgCIvPl0hW-FvGiFosswzq6jCCkaL8GpTQyLNnEnUJhsRNlnREgJ_Abm7GVPrH6JZSl-tzh76eNvHiopQA9jqU70q-yc4HlrQgP4YmncFylrimzIgxYbF1EXEYCI-ru0XpBhIgOMV-yZrwg==" rel="nofollow" target="_blank" title="Rebecca.janzon@microvention.com">Rebecca.janzon@microvention.com</a> About Terumo Neuro We’re in business to create and deliver innovations that redefine what’s possible in neurovascular treatment, meaningfully advancing both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in Aliso Viejo, California, Terumo Neuro products are sold in more than seventy countries through a dedicated sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=Fqe8guy00M4RQhXXGvHQqCBSehaTFEQ_pk3NRHpexm6MTJs130FGH5KOsCueCDEiRupQ8Qo4DagIyjjUlAnAQYd5kW3k_2wU5yVRHBh43Us=" rel="nofollow" target="_blank" title="www.terumoneuro.com">www.terumoneuro.com</a>. About Terumo Corporation Terumo (TSE: 4543) is a global medical innovation company. Guided by an unwavering commitment to patients, and driven by the passion of our associates, we strive to fulfill our Group Mission of “Contributing to Society through Healthcare.” Founded in Tokyo in 1921, we provide a comprehensive range of solutions in the fields of therapeutic procedures, hospital operations, and life sciences in more than 160 countries and regions. References: <ol><li>Fiorella D, Pierot L, Szikora I, et al. The WISE Study - WEB Implant Safety and long-term Effectiveness: a pooled analysis of seven clinical trials – 1-year unruptured aneurysm results. Journal of NeuroInterventional Surgery Published Online First: 17 July 2026. doi: 10.1136/jnis-2026-025724</li><li>Pierot L, Fiorella D, Zhang H, et al. WISE study: 1 year outcomes of Woven EndoBridge treatment for ruptured wide neck bifurcation aneurysms. Journal of NeuroInterventional Surgery Published Online First: 09 July 2026. doi: 10.1136/jnis-2026-025676</li></ol> INDICATIONS FOR USE / INTENDED PURPOSE: The WEB Aneurysm Embolization System is indicated for use at the middle cerebral artery (MCA) bifurcation, internal carotid artery (ICA) terminus, anterior communicating artery (AComm) complex, or basilar artery apex for the endovascular treatment of adult patients with saccular, wide neck bifurcation intracranial aneurysms with dome diameter from 3 mm to 10 mm and either neck size 4 mm or greater or the dome-to-neck ratio is greater than 1 and less than 2. Information provided may not represent the approved indication for use for each country/market. Please refer to the <a href="https://www.globenewswire.com/Tracker?data=uCRXVarttzKhuJoQt70hByEcWbR5tKA_cA--tl46O3cGW36n5iL8zh2-69q8P6VjX4GCwP2vVJ8RcGFc8x7ZDuON4XcFGJUkAXqM--1JNG1IcuIQQzocHKJM8n97aWNK5QBV7LcVCt_VVDIcfT3Ksw==" rel="nofollow" target="_blank" title="Instruction for Use (IFU)">Instruction for Use (IFU)</a> in the specific market/country that you are looking into. <a href="https://www.globenewswire.com/Tracker?data=Fqe8guy00M4RQhXXGvHQqEmnY2BfCp5916wGgrWRTTXP-l_a-gKZjOINJM_1PwgdCdT8qWLy1TX_znZ-7ZHOGnw2n7Q0Q885POdGgy-gMPs=" rel="nofollow" target="_blank" title="www.terumoneuro.com">www.terumoneuro.com</a> Indications, contraindications, warnings, and instructions for use can be found in the product labeling supplied with each device. For Healthcare Professionals Use Only WEB™ is a trademark of MicroVention, Inc., registered in the United States and other jurisdictions. All brand names are   trademarks or registered trademarks owned by TERUMO CORPORATION, its affiliates, or unrelated third parties. All           third-party products are trademarks™ or registered® trademarks and remain the property of their respective holders. MM2437-(i) CA-EMEA-APLA 02/2026 © 2026 MicroVention, Inc. Contact Info Rebecca Janzon <a href="https://www.globenewswire.com/Tracker?data=3dC6iR2-2JDfwCzc1Pd5M87l4N3Z66eBr7QHfxhYyNa0yXMk7AZyima8aE-x2rdsmfK52ZRkmFyq69bAMik6NtWODAEc_1VgSVWaCMgWZvZB4OKt4K5kOT5oI9AJRYoKiP20bKrPPGo-Wf59Hb8lbA==" rel="nofollow" target="_blank" title="rebecca.janzon@microvention.com">rebecca.janzon@microvention.com</a> +1 949-685-4391 
 Attachment

<ul id="gnw_attachments_section-items">
 <li>
 <a target="_blank" href="https://www.globenewswire.com/Tracker?data=u372BT1vyBOzP5BPNeiNiKRW_bz0ApatDR6_GGFvRfpskK7FtFAOXePmSZ5nHLQdrUfzipkdhrE4NMVibnmFYQNDpxvU4uYrI6ZLOtSZzy8SjF0UGw4PnEjBgY7GuXdp7yBcfOTrxq5NzK9SI7rJK8wNorHXbBgeaLFDhFDpoGFvpovMhcSBoUVSL57wmY70" title="Terumo Neuro WISE Study Press Release" rel="nofollow">Terumo Neuro WISE Study Press Release</a>
 </li>
 </ul>
 <img alt="" src='https://ml.globenewswire.com/media/ODIwZWIyNzEtMDc5My00ZjA1LTg0MjEtMjc5YzYwYmFlZDQ5LTUwMDE2MDgyNi0yMDI2LTA4LTMxLWVu/tiny/Terumo-Neuro.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Terumo Neuro Announces Two WISE Study Publications Reporting 0% New Bleeds or Rebleeds Through One Year Following WEB™ Treatment in Ruptured and Unruptured Aneurysm Cohorts

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn